

# NEWSLETTER MARKET COMMUNICATIONS

February 2023



## CHANGES IN THE BOARD OF DIRECTORS

On February 10th the Extraordinary General Meeting approved a proposal to renew Povl-André Bendz, Camilla Huse-Bondesson, Michael Schaefer and Ole Thastrup as non-executive Directors, and the appointment of a new one, Michel Klimkeit.

Michel Klimkeit is an economist by training, with MBA taken in Hamburg and Rotterdam. He started his professional career at an asset management firm, followed by a stint at a German based Fintech. In 2016 he joined Warburg Invest, a German institutional asset manager, in charge of their European small & midcap equity strategy. Later, in 2020 he joined Aretas Family Trust, a multifamily office where he manages the companies' private markets and private equity strategies.

"I am excited to join 2curex at a pivotal moment for the company", Michel said. "I have watched the company transition from its early R&D stage into a commercial organization with presence in over 20 countries and exciting automation initiatives". In his view, "the company is uniquely positioned for the increasing role of guided therapy selection in the oncology field". The appointment stems from an analysis of the company's development, and the competencies required in the upcoming stages. Strengthening the knowledge of the international institutional investor environment was important, and Michael's experience and network in capital markets, his interest in corporate strategy and development, and his extensive experience with healthcare companies, both as an investor and strategic advisor, were a perfect match.

The Board has now very well-balanced knowledge and experience in financial markets, in business development and in medical technologies, which together with the 2cureX management team is a winning combination to bring the company to the next level.

## CHANGES IN INVESTOR'S COMMUNICATIONS

In Vitro Diagnostics is by definition a global industry, and so are its players. 2cureX has always embraced this global perspective in our commercial approach, and although for the time being we have operations only in Europe, our plans and strategies include the whole world.


Now we want to take a similar view in our Investor Relationships. In the past our activity has been focusing mainly on Nordic investors – including Northern Germany, where we have important historic links as a company –, but we will going forward expand and try to reach also investors in other geographies with different profiles.

One consequence is that we will not continue the research and communication services we have had with Redeye since we want to diversify the events and channels we use to interact with investors. We are aiming at increasing our direct communication through webcasts, press releases, website and social media, and also to participate in international investor events that we will be announcing on our website.

The investor meetings we have confirmed attendance in the coming two months are:



[Life Science Conference in Copenhagen](#)



[2023 Swiss Nordic Bio Conference in Zürich](#)



## NEW HEADQUARTERS OF OUR GERMAN AFFILIATE

2cureX GmbH, the German affiliate of 2cureX, moved in January to a new facility in Hamburg. The new space is at the Health Innovation Port <https://www.healthinnovationport.de>, a site for innovative startups in healthcare. The Health Innovation Port is a partnership between Philips, Astra Zeneca, Tekniker Krankenkasse (the largest health insurer in Germany), Asklepios (one of the largest clinic operators in Germany, with 170 sites

and more than 67,000 employees), apoBank and the city of Hamburg.

For 2cureX the HIP is the perfect environment to conduct our activities, with excellent infrastructures, networking opportunities with key healthcare players and located very close to the UKE (University Clinic Hamburg – Eppendorf), our valued long term clinical research partner.

## NEW 2CUREX WEBSITE CHECK IT OUT !

Also in January, we launched our new 2cureX website [www.2curex.com](http://www.2curex.com). With an innovative corporate design, the website is conceived specifically for investors and a general business audience. It has more comprehensive content in the "Investors" and "Governance" sections, and in general an easier navigation experience. Check it out, if you haven't done it yet, and let us know what you think.

Soon, a new IndiTreat® website ([www.inditreat.com](http://www.inditreat.com)) will be launched, this one fully focused on healthcare professionals and patients. We expect, by splitting the websites and tailoring them to specific audiences, we'll be able to better serve the interests of all of them.



# CONTACT US



2cureX Information  
[support@2curex.com](mailto:support@2curex.com)

Product Ordering  
[support@2curex.com](mailto:support@2curex.com)

Fruebjergvej 3,  
2100 Copenhagen, Denmark